Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has entered into new credit agreements with MidCap Financial Trust, which include a $12 million secured term loan at 7% interest and an $8 million secured revolving credit facility at 4.5% interest. These agreements replace the existing loan from OrbiMed, fully repaying that debt. The new financing is aimed at enhancing the company's balance sheet and supporting strategic growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its Q1 2021 financial results on May 11, 2021, before market open. A conference call, led by CEO Sean Browne and CFO Greg Jensen, will take place at 9:00 AM ET on the same day to discuss the results. Interested parties can join the call using the provided dial-in numbers or register for the webcast. The company specializes in surgical solutions for spinal disorders, including orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that it is not aware of any undisclosed corporate developments accounting for the recent surge in its share price and trading volume. The company focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implant systems. Their commitment to integrity and customer service remains a priority as they navigate the market fluctuations.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has successfully closed a $20 million private placement with a healthcare-focused institutional investor. The deal involved the sale of 8,888,890 common shares and warrants for 6,666,668 shares, at a price of $2.25 each. Net proceeds after fees are approximately $18.4 million, intended for working capital and other corporate purposes. The warrants are exercisable at the same price, expiring in five years. Sean Browne, President and CEO, expressed that this funding will support growth initiatives and enhance shareholder value.
Xtant Medical Holdings, Inc. (XTNT) reported fourth quarter 2020 revenue of $14.0 million, down from $17.0 million a year earlier, primarily impacted by COVID-19. However, operating expenses decreased to $8.7 million from $11.7 million, leading to a narrower net loss of $0.7 million or $0.01 per share, compared to a loss of $1.6 million in Q4 2019. The company announced a $20 million private placement to enhance working capital. Despite revenue declines, there is positive momentum toward recovery as elective procedures rebound.
Xtant Medical Holdings (NYSE American: XTNT) has entered into a definitive agreement for a private placement to raise approximately $20 million. The agreement includes the sale of 8,888,890 common shares and warrants to purchase 6,666,668 common shares, priced at $2.25 each. Proceeds will be used for working capital and corporate purposes. The placement is expected to close around February 24, 2021, pending regulatory approvals. A.G.P./Alliance Global Partners is the sole placement agent.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for the fourth quarter and full year ended December 31, 2020, on February 24, 2021, before market open. The results will be discussed in a conference call at 9:00 AM ET the same day, led by CEO Sean Browne and CFO Greg Jensen. Investors can join the call at 877-407-6184 or through international dial-in at 201-389-0877. A replay will be available on the company's website post-call. Xtant Medical specializes in surgical solutions for spinal disorders.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that the subscription period for its rights offering expired on December 4, 2020. The company expects to issue approximately 711,143 shares at a subscription price of $1.07, generating gross proceeds of around $761,000. This is based on preliminary results from EQ Shareowner Services. The offering's final results await verification. The company’s SEC registration statement was effective as of November 3, 2020. Interested parties can find more details on the SEC's website.
Xtant Medical Holdings reported third-quarter 2020 revenues of $14.0 million, a 33% increase from Q2 2020 but a 10.9% decline year-over-year. Operating expenses fell to $8.5 million from $11.1 million in Q3 2019, aiding an income from operations of $0.8 million. The net loss was $1.4 million, improved from a loss of $1.9 million in Q3 2019. Adjusted EBITDA rose to $1.6 million, up from $0.6 million a year ago. The company also announced a proposed rights offering of up to $15 million of common stock.
Xtant Medical Holdings (XTNT) has announced a rights offering of up to $15 million in common stock, with a record date set for November 5, 2020. Each stockholder will receive subscription rights enabling them to purchase shares at a price of $1.07 per share. The offering begins on November 5, 2020, pending registration approval, and concludes on December 4, 2020, with over-subscription privileges available. The company intends to distribute subscription materials by November 6, 2020. This offering aims to bolster Xtant's funding for developing surgical solutions for spinal disorders.